A Phase 3 Randomized Double-Blind Study of Pamrevlumab or Placebo in combination with Gemcitabine Plus Nab-Paclitaxel as Neoadjuvant Treatment in Patients with Locally Advanced Unresectable Pancreatic Cancer

Brief description of study

The purpose of this study is find out if the if the investigational drug, pamrevlumab, can be used to treat pancreatic cancer. FibroGen, Inc. (FibroGen), the study sponsor, is responsible for developing pamrevlumab. Pamrevlumab is called “investigational” because the drug has not been approved by the U.S. Food and Drug Administration (FDA), or by any other health authority in any country, for doctors to prescribe to their patients. Pamrevlumab is a type of protein drug called a human monoclonal antibody. Monoclonal antibodies are similar to the antibodies that your body normally produces. Antibodies are made by your immune system and help you fight infections.


Clinical Study Identifier: s18-01389
ClinicalTrials.gov Identifier: NCT03941093
Principal Investigator: Paul E. Oberstein.


If you are registered as a volunteer, please login to the dashboard to send referrals.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.